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Abstract
The definition of what constitutes a ‘normal’ adrenal response to
critical illness is unclear. Consequently, published studies have
used a variety of biochemical criteria to define ‘adrenal
insufficiency’. These criteria have been based on the baseline
cortisol level or the increment in cortisol following corticotropin
administration. However, in critically ill patients there are a number
of confounding factors that make interpretation of these tests
difficult. Furthermore, in those patients who are most likely to
benefit from treatment with low-dose glucocorticoids, there is no
evidence that treatment should be based on adrenal function
testing. In those patients in whom the diagnosis of adrenal
insufficiency may be important, this diagnosis may best be made
based on the free cortisol level or the total cortisol level stratified
by serum albumin.
The definition of what constitutes a ‘normal’ adrenal response
to critical illness is unclear [1]. Consequently, published
studies have used a variety of biochemical criteria to define
abnormalities in adrenal function during critical illness. These
criteria have been based on the ‘stress’ (baseline) cortisol
level or the increment in cortisol (delta cortisol) following
administration of 250 µg corticotropin. However, in critically ill
patients there are a number of confounding factors that make
interpretation of these tests difficult. Most importantly, the
commercially available assays for serum cortisol determine
the total (free plus protein-bound fractions) hormone concen-
trations. In healthy individuals more than 90% of circulating
cortisol is bound to corticosteroid-binding globulin (CBG),
with less than 10% in the free, biologically active form. In
critical illness CBG levels fall by approximately 50%, with
marked interindividual variation. Furthermore, as CBG binding
sites becomes saturated the percentage of free cortisol
increases. Hence, in critically ill patients the total cortisol may
not reflect the biologically free (unbound) cortisol.
In a cohort of critically ill patients, Hamrahian and colleagues
[2] demonstrated that patients who were hypoproteinemic
(serum albumin <2.5 g/dl) had significantly lower total
baseline and stimulated cortisol levels as compared with
patients who had a serum albumin above 2.5 g/dl, but the
free baseline and free stimulated cortisol concentrations were
similar. The importance of serum albumin (a surrogate marker
of CBG levels) when interpreting total serum cortisol
concentrations is elegantly demonstrated by the study
conducted by Salgado and colleagues [1], which appeared in
the previous issue of Critical Care. Those investigators
performed a low-dose (1 µg) and high-dose (249 µg) cortico-
tropin stimulation test in 102 patients in septic shock. The
total baseline and stimulated cortisol levels were significantly
lower in patients with a serum albumin below 2.5 g/dl than in
those with a serum albumin above 2.5 g/dl. However, unlike
the study by Hamrahian and colleagues [2], the delta cortisol
was similar between groups.
The specificity, sensitivity, and performance of the
commercially available assays are not uniform [3]. This further
complicates the interpretation of the serum cortisol level. It is
speculated that the variation in assay characteristics might be
even more significant in critically ill patients, especially those
with septic shock. The presence of interfering heterophile
antibodies may account for this observation [4]. The most
specific assay employs the use of mass spectrometry, but
this test is not commonly available. To complicate matters
further, patients may develop critical illness related cortico-
steroid insufficiency (CIRCI), despite ‘adequate’ free levels of
cortisol, due to tissue resistance. Tissue resistance to cortisol
may occur as a result of abnormalities in the glucocorticoid
receptor or increased tissue conversion of cortisol to
cortisone.
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In those patients who are most likely to benefit from ‘low-
dose’ glucocorticoids (those patients with severe sepsis,
septic shock, and acute respiratory distress syndrome
[ARDS]), it is not clear whether treatment should be based
on the results of adrenal function testing. Confalonieri and
colleagues [5] randomized 48 patients with severe
community-acquired pneumonia to receive low-dose
hydrocortisone or placebo. Similarly, Meduri and coworkers
[6] randomized 91 patients with early ARDS to receive low-
dose methylprednisolone or placebo. In both of these studies
patient outcome was improved in the steroid-treated group,
independent of adrenal function testing. Five randomized,
placebo-controlled studies have evaluated low-dose
hydrocortisone (200-300 mg/day) in patients with septic
shock [7-11]. A meta-analysis of these studies demonstrated
more rapid shock reversal and a survival benefit from
corticosteroids [12]. The benefit in terms of shock reversal
was seen in both corticotropin responders (delta cortisol
>9 mg/dl) and nonresponders (delta cortisol <9 mg/dl;
Figure 1). In the study by Salgado and colleagues [1] a
baseline cortisol of 23.6 mg/dl was the best discriminator of
hemodynamic response to corticosteroid treatment. This is
remarkably similar to the threshold of 23.7 µg/dl that we
previously reported [13]. This finding suggests that patients
with septic shock, and perhaps those with early ARDS and
severe community-acquired pneumonia, should be treated
with low-dose corticosteroids independent of adrenal
function testing. It is, however, unclear at this time whether
patients with high serum cortisol levels (>25 µg/dl) will
benefit from treatment with corticosteroids.
Although the diagnosis of ‘adrenal insufficiency’ may not be
clinically relevant in most critically ill patients, there may be
groups of patients in whom this diagnosis may be important.
Figure 1
Meta-analysis. Summarized is a meta-analysis of the effect of treatment with low-dose hydrocortisone on shock reversal at day 7 in patients with
septic shock grouped by response to cosyntropin.
Table 1
Diagnostic criteria for adrenal insufficiency
Albumin Albumin 
>2.5 g/dl <2.5 g/dl
Total cortisol (µg/dl [nmol/l])
Baseline 15 (410) 10 (275)
Stimulated 20 (550) 15 (410)
Free cortisol (µg/dl [nmol/l])
Baseline 1.8 (50) 1.8 (50)
Stimulated 3.0 (85) 3.0 (85)Page 3 of 3
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This would include patients with adrenal hemorrhage/
infarction, as well as patients with liver disease, head injury,
pancreatitis, and burns, among others. At this time the
diagnosis of adrenal insufficiency in these patients may best
be made based on the free cortisol level or the total cortisol
level stratified by serum albumin (Table 1) [14,15]. Because
these criteria are based on limited data, it is likely that these
diagnostic thresholds will be refined with time. However, it is
important to stress that the diagnosis of adrenal insufficiency
in critically ill patients should not be made on the basis of
laboratory criteria alone.
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